Victor Antonio Rivera, MD | |
1035 Nider Blvd # 100, Virginia Beach, VA 23459-8701 | |
(757) 953-8351 | |
Not Available |
Full Name | Victor Antonio Rivera |
---|---|
Gender | Male |
Speciality | Anesthesiology - Pain Medicine |
Location | 1035 Nider Blvd # 100, Virginia Beach, Virginia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225265200 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 0101248044 (Virginia) | Secondary |
207LP2900X | Anesthesiology - Pain Medicine | 0101248044 (Virginia) | Primary |
Entity Name | Smg Anesthesia Specialists Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1518205004 PECOS PAC ID: 6305081118 Enrollment ID: O20130327000494 |
News Archive
Worldwide, there are more than 1.5 billion overweight adults, including 400 million who are obese. In Australia, it is estimated more than 50 per cent of women and 60 per cent of men are either overweight or obese.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.
A little empathy can go a long way toward ending infectious disease outbreaks. That's a conclusion from researchers at the Georgia Institute of Technology, who used a networked variation of game theory to study how individual behavior during an outbreak of influenza - or other illness - affects the progress of the disease, including how rapidly the outbreak dies out.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Victor Antonio Rivera, MD 620 John Paul Jones Cir, Portsmouth, VA 23708-2111 Ph: (757) 953-3238 | Victor Antonio Rivera, MD 1035 Nider Blvd # 100, Virginia Beach, VA 23459-8701 Ph: (757) 953-8351 |
News Archive
Worldwide, there are more than 1.5 billion overweight adults, including 400 million who are obese. In Australia, it is estimated more than 50 per cent of women and 60 per cent of men are either overweight or obese.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.
A little empathy can go a long way toward ending infectious disease outbreaks. That's a conclusion from researchers at the Georgia Institute of Technology, who used a networked variation of game theory to study how individual behavior during an outbreak of influenza - or other illness - affects the progress of the disease, including how rapidly the outbreak dies out.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
› Verified 9 days ago
Gary Jay Waxman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 816 Independence Blvd, Ste 2a, Virginia Beach, VA 23455 Phone: 757-363-6712 Fax: 757-363-6204 | |
Dr. Daphne Michelle Lenox, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 134 Business Park Dr, Virginia Beach, VA 23462 Phone: 757-473-0055 | |
Dr. Stephen Michael Bronaugh, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 134 Business Park Dr, Virginia Beach, VA 23462 Phone: 757-473-0044 | |
Francis T Verfurth, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1060 First Colonial Rd, Virginia Beach, VA 23454 Phone: 757-395-8369 | |
George N Vretakis, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 138 S Rosemont Rd, Ste 215, Virginia Beach, VA 23452 Phone: 757-431-9551 Fax: 757-431-9663 | |
Dr. Jennifer Nicole Georgi, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 134 Business Park Dr, Virginia Beach, VA 23462 Phone: 757-473-0044 | |
Dr. Monford Wolf, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1975 Glenn Mitchell Dr, Suite 300, Virginia Beach, VA 23456 Phone: 757-507-0170 |